This program aims to develop a cocktail of bacteriophages — specialized viruses that target bacteria — to treat chronic Pseudomonas infections in the lungs of people with CF.

Researchers will enhance these phages with gene editing technology that would improve the ability of these viruses to infect and kill the bacteria and use the bacteria to produce and release particles that break up biofilms. Altogether, these engineered features are expected to produce a phage therapy designed to eliminate persistent Pseudomonas infections and be tested in clinical trials. 

Status

Laboratory studies to develop and test this potential therapy are underway.

Sponsor

This program is sponsored by SNIPR Biome and partially funded by the Cystic Fibrosis Foundation.